Meritxell Bellet

Also affiliated with Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT”.

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

Journal of Clinical Oncology(2022)10.1200/jco.22.01065

N/A

2.2DataRank · unranked

59 citations

Gini F. Fleming, István Láng, Eva Ciruelos, Hervé Bonnefoi, Meritxell Bellet +22 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Nature Communications(2022)10.1038/s41467-022-32828-6

N/A

0.721DataRank · unranked

121 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1796

N/A

0.680DataRank · unranked

24 citations

Meritxell Bellet, Nicholas C. Turner, Sherene Loi, Aditya Bardia, Valentina Boni +17 more

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

Annals of Oncology(2023)10.1016/j.annonc.2023.01.009

N/A

0DataRank · unranked

48 citations

Giuseppe Viale, Serena Nik‐Zainal, Peter Savas, Roswitha Kammler, Patrizia Dell’Orto +33 more

Data from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

(2023)10.1158/0008-5472.c.6513876.v1

N/A

0DataRank · unranked

0 citations

Andrea Herencia-Ropero, Alba Llop‐Guevara, Flaminia Pedretti, Alejandro Moles‐Fernández, Cristina Viaplana +34 more

Data from Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

(2024)10.1158/1078-0432.c.7077719

N/A

0DataRank · unranked

0 citations

Meritxell Bellet, Nicholas C. Turner, Sherene Loi, Aditya Bardia, Valentina Boni +17 more

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

Genome Medicine(2020)10.1186/s13073-020-00774-x

N/A

0DataRank · unranked

23 citations

Miquel Duran‐Frigola, Albert Gris‐Oliver, Marta Palafox, Maurizio Scaltriti, Pedram Razavi +6 more

Data from Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

(2024)10.1158/1078-0432.c.7077719.v1

N/A

0DataRank · unranked

0 citations

Meritxell Bellet, Nicholas C. Turner, Sherene Loi, Aditya Bardia, Valentina Boni +17 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Research Square(2021)10.21203/rs.3.rs-236645/v1

N/A

0DataRank · unranked

12 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Cancer Research(2022)10.1158/0008-5472.can-21-2409

N/A

0DataRank · unranked

98 citations

Andrea Herencia-Ropero, Alba Llop‐Guevara, Flaminia Pedretti, Alejandro Moles‐Fernández, Cristina Viaplana +34 more